Oncology and Immunology continue to be thriving powerhouse segments for Johnson & Johnson, driving significant revenue

Worldwide revenue (in millions USD) for the second quarter (Q2) of 2025, the first half (H1) of 2025, and 2024 for the top 10 Johnson & Johnson's (J&J) marketed drugs.

(Please use a modern browser to see the interactive version of this visualization)

Chart: © Phalguni Deswal, Drug and Device World (www.druganddeviceworld.com)Source: J&J's financial disclosuresDownload imageCreated with Datawrapper